Datapoint: FDA Expands Cibinqo’s Atopic Dermatitis Approval

February 21

The FDA on Feb. 10 expanded Pfizer’s Cibinqo’s approved use in atopic dermatitis. Its use now includes patients age 12 to 18 with “with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable,” according to a Pfizer press release. For the treatment of atopic dermatitis, the JAK inhibitor currently holds covered or better status for 78% of all insured lives under the pharmacy benefit. About 22% of covered lives have preferred access to Cibinqo, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 2/15/23